Oral fluoropyrimidines in cancer treatment.

This publication has 27 references indexed in Scilit:

• Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patients
  European Journal Of Cancer, 1998
• Phase I Trial ofU racil-Tegafur (UFT) plus Oral Leucovorin: 28-Day Schedule
  Cancer Investigation, 1998
• A Comparative, Randomized Trial of UFT® and 5-Fluorouracil in Combination with Cyclophosphamide and Doxorubicin in the Treatment of Advanced Breast Cancer Patients at The Philippines General Hospital
  Oncology, 1997
• Phase I trials of uracil-tegafur (UFT) using 5 and 28 day administration schedules
  Anti-Cancer Drugs, 1996
• Phase III Study of Bolus Versus Infusion Fluorouracil With or Without Cisplatin in Advanced Colorectal Cancer
  JNCI Journal of the National Cancer Institute, 1996
• Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study
  European Journal Of Cancer, 1995
• 5-Ethynyluracil (776C85): Protection from 5-fluorouracil-induced neurotoxicity in dogs
  Biochemical Pharmacology, 1994
• A Cooperative Randomized Study on Tegafur plus Mitomycin C versus Combined Tegafur and Uracil plus Mitomycin C in the Treatment of Advanced Gastric Cancer
  Japanese Journal of Cancer Research, 1991
• A Randomized Controlled Postperative Adjuvant Chemotherapy Trial of MMC+Tegafur and MMC+UFT for Adenocarcinoma of the Lung. First Study. (Second Report).
  Haigan, 1991
• A review of the United States clinical experience of the fluoropyrimidine, ftorafur (NSC-148958)
  Cancer Treatment Reviews, 1980